

UNCLASSIFIED

Exhibit R-2, RDT&E Budget Item Justification: PB 2022 Defense Health Agency **Date:** May 2021

Appropriation/Budget Activity 0130: <i>Defense Health Program I BA 2: RDT&E</i>					R-1 Program Element (Number/Name) PE 0607100DHA I <i>Medical Products and Capabilities Enhancement Activities</i>							
COST (\$ in Millions)	Prior Years	FY 2020	FY 2021	FY 2022 Base	FY 2022 OCO	FY 2022 Total	FY 2023	FY 2024	FY 2025	FY 2026	Cost To Complete	Total Cost
Total Program Element	113.416	16.819	17.215	17.619	-	17.619	0.000	0.000	0.000	0.000	Continuing	Continuing
377A: <i>GDF-Medical Products and Capabilities Enhancement Activities</i>	109.698	16.819	17.215	17.619	-	17.619	-	-	-	-	Continuing	Continuing
457A: <i>AF Advanced Technology Development – Rapid Technology Transition</i>	1.336	0.000	0.000	0.000	-	0.000	-	-	-	-	Continuing	Continuing
700A: <i>CSI - Congressional Special Interests</i>	2.382	0.000	0.000	0.000	-	0.000	-	-	-	-	Continuing	Continuing

Note

N/A

A. Mission Description and Budget Item Justification

Guidance for Development of the Force-Medical Products and Capabilities Enhancement Activities: Funds will support developmental upgrades to medical systems, training systems, and products that have been fielded, are routinely used in a fixed facility, or that have been approved for full-rate production and for which procurement funding is anticipated in the current fiscal year or subsequent fiscal years. These funds will support testing and evaluation for the enhancement of fielded or procured medical systems/products and medically-related information technology systems, assessment of fielded medical products or medical practices in order to identify the need/opportunity for changes, and analyses of clinical intervention outcomes to enhance and improve indications for pharmaceutical products. Efforts address the Military Health System Concept of Operations documents and follow-on Capabilities Based Assessments/Joint Capability Documents, appropriate Component requirements, legislative and Executive directives, and others as appropriate. Coordination occurs through the planning and execution activities of the Defense Health Agency Component Acquisition Executive (DHA CAE).

UNCLASSIFIED

Exhibit R-2, RDT&E Budget Item Justification: PB 2022 Defense Health Agency	Date: May 2021
--	-----------------------

Appropriation/Budget Activity 0130: <i>Defense Health Program I BA 2: RDT&E</i>	R-1 Program Element (Number/Name) PE 0607100DHA I <i>Medical Products and Capabilities Enhancement Activities</i>
---	---

B. Program Change Summary (\$ in Millions)	FY 2020	FY 2021	FY 2022 Base	FY 2022 OCO	FY 2022 Total
Previous President's Budget	16.819	17.215	17.619	-	17.619
Current President's Budget	16.819	17.215	17.619	-	17.619
Total Adjustments	0.000	0.000	0.000	-	0.000
• Congressional General Reductions	-	-			
• Congressional Directed Reductions	-	-			
• Congressional Rescissions	-	-			
• Congressional Adds	-	-			
• Congressional Directed Transfers	-	-			
• Reprogrammings	-	-			
• SBIR/STTR Transfer	-	-			

Change Summary Explanation

N/A

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2022 Defense Health Agency										Date: May 2021		
Appropriation/Budget Activity 0130 / 2					R-1 Program Element (Number/Name) PE 0607100DHA / Medical Products and Capabilities Enhancement Activities				Project (Number/Name) 377A / GDF-Medical Products and Capabilities Enhancement Activities			
COST (\$ in Millions)	Prior Years	FY 2020	FY 2021	FY 2022 Base	FY 2022 OCO	FY 2022 Total	FY 2023	FY 2024	FY 2025	FY 2026	Cost To Complete	Total Cost
377A: GDF-Medical Products and Capabilities Enhancement Activities	109.698	16.819	17.215	17.619	-	17.619	-	-	-	-	Continuing	Continuing

A. Mission Description and Budget Item Justification

Guidance for Medical Products and Capabilities Enhancement Activity: This funding supports enhancement of existing medical products and medically related information technology systems to further fielding of joint medical materiel capabilities to meet Warfighter needs through support testing and evaluation for the enhancement of fielded or procured medical systems/products and medically-related information technology systems, assessment of fielded medical products or medical practices in order to identify the need/opportunity for changes, and analyses of clinical intervention outcomes to enhance and improve indications for pharmaceutical products.

B. Accomplishments/Planned Programs (\$ in Millions)

	FY 2020	FY 2021	FY 2022
Title: 377A: GDF – Medical Products and Capabilities Enhancement Activities	16.819	17.215	17.619
Description: This funding provides support for developmental efforts to upgrade medical products and capabilities that have been fielded or have received approval for full rate production and anticipate production funding in the current or subsequent fiscal year. These funds will support testing and evaluation for the enhancement of fielded or procured medical systems/products and medically-related information technology systems, assessment of fielded medical products or medical practices in order to identify the need/opportunity for changes, and analyses of clinical intervention outcomes to enhance and improve indications for pharmaceutical products.			
FY 2021 Plans: Funding will be used to modernize and upgrade products through joint testing and evaluation to improve fielding and procurement of medical materiel products. Programs for enhancement include: an assessment of a novel video laryngoscope for far-forward endotracheal intubation; evaluation of markerless-based motion capture technology as a screening tool for musculoskeletal injury; evaluation of a longer-acting sleep aid for military operations; expanding the use of a hemostatic device to control bleeding in wounded areas where a tourniquet cannot be utilized; and enhance a burn navigator application for care of burn patients in an operational setting.			
FY 2022 Plans: FY 2022 plans continue efforts as outlined in FY 2021 and support upgrades necessary to modernize Adenovirus manufacturing obsolescence of fielded medical equipment and devices.			
FY 2021 to FY 2022 Increase/Decrease Statement:			

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2022 Defense Health Agency		Date: May 2021
Appropriation/Budget Activity 0130 / 2	R-1 Program Element (Number/Name) PE 0607100DHA / <i>Medical Products and Capabilities Enhancement Activities</i>	Project (Number/Name) 377A / <i>GDF-Medical Products and Capabilities Enhancement Activities</i>

B. Accomplishments/Planned Programs (\$ in Millions)	FY 2020	FY 2021	FY 2022
Pricing adjustment for inflation.			
Accomplishments/Planned Programs Subtotals	16.819	17.215	17.619

C. Other Program Funding Summary (\$ in Millions)

N/A

Remarks

D. Acquisition Strategy

This program will integrate product improvements and enhancements resulting from post marketing studies and surveillance in existing medical products and medically related information technology systems to better meet Warfighter needs.

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2022 Defense Health Agency **Date:** May 2021

Appropriation/Budget Activity 0130 / 2	R-1 Program Element (Number/Name) PE 0607100DHA / <i>Medical Products and Capabilities Enhancement Activities</i>	Project (Number/Name) 457A / <i>AF Advanced Technology Development – Rapid Technology Transition</i>
--	---	--

COST (\$ in Millions)	Prior Years	FY 2020	FY 2021	FY 2022 Base	FY 2022 OCO	FY 2022 Total	FY 2023	FY 2024	FY 2025	FY 2026	Cost To Complete	Total Cost
457A: <i>AF Advanced Technology Development – Rapid Technology Transition</i>	1.336	0.000	0.000	0.000	-	0.000	-	-	-	-	Continuing	Continuing

A. Mission Description and Budget Item Justification

Air Force - Medical Products and Capabilities Enhancement Activities: Funds support a developmental upgrade to a medical product that has been fielded and for which procurement funding is anticipated subsequent fiscal years.

B. Accomplishments/Planned Programs (\$ in Millions)

	FY 2020	FY 2021	FY 2022
Title: AF Advanced Technology Development – Rapid Technology Transition	0.000	-	-
Description: Provide support for developmental efforts to upgrade medical products and capabilities that have been fielded or have received approval for full rate production and anticipate production funding in the current or subsequent fiscal year.			
Accomplishments/Planned Programs Subtotals	0.000	-	-

C. Other Program Funding Summary (\$ in Millions)

N/A

Remarks

\$1.1M FY15/17 Defense Health Program – Air Force Procurement funds

D. Acquisition Strategy

Cost-plus Fixed Fee contract award to performer via the Army-Natick Soldier Systems Research Development and Execution Center contracting activity.

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2022 Defense Health Agency **Date:** May 2021

Appropriation/Budget Activity 0130 / 2					R-1 Program Element (Number/Name) PE 0607100DHA / <i>Medical Products and Capabilities Enhancement Activities</i>				Project (Number/Name) 700A / <i>CSI - Congressional Special Interests</i>			
COST (\$ in Millions)	Prior Years	FY 2020	FY 2021	FY 2022 Base	FY 2022 OCO	FY 2022 Total	FY 2023	FY 2024	FY 2025	FY 2026	Cost To Complete	Total Cost
700A: <i>CSI - Congressional Special Interests</i>	2.382	0.000	0.000	0.000	-	0.000	-	-	-	-	Continuing	Continuing

Note

N/A

A. Mission Description and Budget Item Justification

Congressional Special Interest (CSI) funding directed toward core research initiatives in Program Element (PE) 0607100 - Medical Products and Capabilities Enhancement Activities.

B. Accomplishments/Planned Programs (\$ in Millions)

N/A

C. Other Program Funding Summary (\$ in Millions)

N/A

Remarks

N/A

D. Acquisition Strategy

N/A